Project aims

PneumoNP in the nanomedicine value chain

PneumoNP is a research project funded under the European Union’s Seventh Framework Programme, involving 11 teams, from 6 different countries. These partners will actively cooperate in the nanomedicine value chain as far as preclinical validation from 2014 to 2017.

Nanomedicine value chain

Expected outcomes

The main objective of the project is the development of a theragnostic system for the treatment of resistant Gram-negative bacterial infections in lungs. A majority of international stakeholders from the healthcare sector agree that infections due to antibiotic resistant Gram-negative bacteria are one of the major issues currently affecting global health, largely due to a lack of effective antibiotic therapy for this type of infection. The PneumoNP team will therefore specifically focus its attention on the pathogen Klebsiella pneumoniae, a global cause of antibiotic resistant infections.

Klebsiella pneumoniae

PneumoNP will generate:

  • a new inhalable drug system composed of a nanotherapeutic system combining an antimicrobial peptide or active pharmaceutical ingredient (API) and a nanocarrier;
  • a new aerosol technology specifically developed for the nanotherapeutic system;
  • an innovative efficiency-efficacy test to follow-up the treatment;
  • a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections.

Find out how the PneumoNP work will be carried out and divided into work packages from 2014 to 2017.

If you want to know more about the project’s news, subscribe to our newsletter, follow us on Twitter or join us on LinkedIn.